Karpo has launched VibePad, a mood-based discovery tool built on Apple Intelligence, and Karpo Browser, an AI booking agent that reserves restaurants, tickets and classes, so users go from a feeling to a booked night out in one app. Karpo is the app that always knows the move, and now it can make it happen. As the iPhone 18 series and iPhone Duo put Apple Intelligence in the spotlight, Karpo makes planning feel more intuitive with a mood slider and an AI booking agent.

United States, 21st Oct 2026 – Karpo (app.karpo.ai), New York’s AI sidekick for going out, today announced Karpo Browser, an AI booking agent inside the Karpo app that completes restaurant reservations, ticket purchases and class bookings once users confirm the details. Karpo Browser joins VibePad, a new way to discover what to do based on your mood, built natively on Apple Intelligence, so users can go from a feeling to a confirmed plan in one app. Karpo is free on iPhone and available now on the APP Store in multiple countries.

“We built Karpo around a very New York problem: endless options and group chats that end in ‘idk, you pick,’” said Titus, Head of Growth at Karpo. “Karpo turns that indecision into one specific plan. This fall, as New York fills with concerts, food events and holiday energy, we want VibePad in people’s hands: more saying yes, more city, and a more interesting New York. You bring the vibe, and Karpo does the rest.”

Why It Matters: Good plans rarely fall apart for lack of ideas. They fall apart between “we should” and “we did,” somewhere across five open tabs. Karpo is not another chatbot, but a way to get off your phone and into the city, and it closes a gap that existing tools leave open:

• Chatbots make users spell out what they want in words.
• Recommendation apps stop at a list and leave the booking to the user.
• Booking apps only help once users already know where to go.

Start with a feeling, and Karpo finds the nights worth saying yes to, then books them.

From a Vibe to a Booking: How VibePad and Karpo Browser Work

When a user types a quick request such as dinner in the Village, Karpo recognizes the intent and opens VibePad. With a slide of the thumb and no extra words, the user moves toward the kind of night they want, from Buzzing to Chill and Solo to Social, and Karpo builds a plan around wherever they land. Dead center just says “surprise me.”

Nobody lives in the middle. Built natively on Apple Intelligence through Apple’s Foundation Models framework, VibePad runs on-device and only on Karpo, turning AI into something simple and useful: helping people decide what to do and actually go do it.

Karpo Browser then turns that feeling into a confirmed plan. It searches the web on the user’s behalf, finds the dinner reservation, concert tickets or a spot in Saturday’s ceramics class, and fills out the forms. Users authorize the task and confirm the details, and Karpo completes the booking while they get on with their day.

About Karpo

Karpo is New York’s AI sidekick for going out, developed by MachinePulse Pte. Ltd. Users start with a feeling, and Karpo finds, plans and books the nights worth saying yes to. Karpo is available as a free download on the App Store for iPhone. Learn more at https://app.karpo.ai.

Media Contact

partnership@machinepulse.ai

Media Contact

Organization: Karpo AI

Contact Person: Titus

Website: https://app.karpo.ai/

Email: Send Email

Country: United States

Release id: 50082

View source version on King Newswire:
Karpo Launches Karpo Browser and VibePad to Turn a Mood Into a Booked Night Out in One App

Singapore, October 21st, 2026 – Businesses across industries are increasingly investing in technologies that improve efficiency, connect systems, and support data-driven decision-making. As AI adoption accelerates, organizations are shifting their focus from standalone tools to integrated technology ecosystems that deliver measurable business value.

According to technology consultancy Global TechHouse, the next phase of digital transformation will be defined by the combination of custom software, intelligent automation, and connected business infrastructure.

The company provides a range of technology services including Web Development, CRM Development, AI & Automation, API Integrations, Dashboard & Analytics, and Domain & Hosting Management. Together, these solutions help businesses reduce manual workloads, improve visibility, and create more efficient operational processes.

One area seeing significant growth is AI-powered automation, where organizations are using intelligent workflows to streamline repetitive tasks, improve accuracy, and free teams to focus on strategic initiatives. At the same time, integrated CRM systems and API-driven connectivity are helping businesses centralize information and improve customer experiences.

Data analytics is also becoming a critical component of modern business strategy. Through customized dashboards and reporting systems, organizations gain access to real-time insights that support faster and more informed decision-making.

“The conversation around AI is evolving,” said David Johnson, Ultimate Beneficial Officer(UBO) at Global TechHouse. “Businesses are no longer looking for technology simply because it’s new. They want solutions that improve operations, connect systems, and generate measurable outcomes. That’s where custom software and intelligent automation create real value.”

As digital transformation continues to evolve, businesses that successfully combine automation, analytics, and scalable infrastructure are expected to be better positioned for growth, adaptability, and long-term competitiveness.

About Global TechHouse

Global TechHouse (GTH) is a technology consulting and software engineering company delivering custom web development, CRM solutions, AI & Automation, API Integrations, Dashboard & Analytics platforms, and Digital Infrastructure Services. The company helps organizations build scalable, efficient, and future-ready technology solutions that support long-term business growth.

To know more, visit website – https://globaltechhouse.io/ 

Maylene has launched its UK research peptide platform, offering laboratory research compounds, product information and third-party testing reports, with a focus on transparency, scientific documentation and responsible research.

The newly launched online platform brings together research peptide pens, compound information and laboratory reports as scrutiny of the research peptide market continues to grow.

United Kingdom, 21st Oct 2026 — Maylene, a UK-focused supplier of research peptides and laboratory products, has announced the launch of its online platform, maylene.uk, offering a catalogue of research compounds alongside product information, laboratory documentation and educational resources.

The launch comes as peptides continue to attract attention across biotechnology, metabolic research and experimental science. Although some peptide-based medicines have established clinical applications, many compounds discussed in online communities remain investigational, with limited human evidence or no regulatory approval for therapeutic use.

This distinction has become increasingly important as scientific research, commercial interest and public discussion of peptides increasingly overlap.

Maylene enters this market with a catalogue of 19 products, including 16 research pens and three product bundles. The collection includes compounds such as retatrutide, BPC-157, GHK-Cu and NAD+, spanning different areas of laboratory research.

Rather than presenting these compounds as established treatments, the company states that its products are intended exclusively for laboratory and scientific research, not for human or veterinary use.

Documentation and Transparency in a Developing Market

One of the challenges facing research peptide buyers is understanding the difference between a product’s labelled specifications and independently documented laboratory results.

Certificates of Analysis can provide useful information about a tested sample, including compound identity and purity. However, a certificate alone does not establish clinical safety, therapeutic effectiveness or the characteristics of every batch supplied commercially.

Maylene’s website includes a laboratory report library linking to published analytical records from Janoshik, a third-party testing provider. At launch, the library lists eight reports associated with seven products.

The company also identifies products without matching published reports and advises buyers to verify documentation for the exact product and batch before relying on testing information.

This approach reflects a broader need for clearer scientific documentation in the research chemical supply market, where analytical verification and responsible interpretation of results remain important considerations.

A Platform Beyond Product Listings

Alongside its catalogue, Maylene has introduced educational content exploring peptide research, compound comparisons and scientific topics receiving public attention.

The platform also provides product specifications, ordering guidance, documentation enquiries and information about research-use restrictions.

Maylene lists free UK delivery, with international shipping available to eligible destinations for a flat charges. The company also accepts enquiries relating to bulk and institutional research requirements.

The online catalogue is intended to support researchers and procurement teams seeking to compare available compounds, formats and accompanying documentation before making purchasing decisions.

Scientific Interest Does Not Equal Clinical Approval

The wider interest in peptides also raises questions about how preliminary research findings are communicated.

Results from laboratory experiments or animal studies do not necessarily translate into effective or safe treatments for humans. Even promising investigational compounds require appropriate clinical evaluation before claims about safety and effectiveness can be established.

For suppliers operating in this field, clearly distinguishing research materials from approved medicines is an important part of responsible communication.

Maylene states that its products are supplied solely for laboratory research and are not intended for consumption, clinical administration or veterinary applications.

Looking Ahead

With its website now live, Maylene joins a growing number of specialist suppliers serving the research peptide market.

Its development will take place against a backdrop of continued scientific interest and increasing attention to analytical standards, product traceability and the appropriate communication of experimental research.

As the market evolves, the availability of reliable product-specific information and independently verifiable documentation will remain important factors for laboratories and research organisations evaluating suppliers.

About Maylene

Maylene is a research peptide and laboratory product supplier serving the UK market and eligible international destinations. Its online platform features research peptide pens, product bundles, scientific information and a library of available laboratory reports. All products are intended strictly for laboratory and scientific research and are not for human or veterinary use.

Website: https://www.maylene.uk/

Laboratory documentation: https://www.maylene.uk/certificates

Company information: https://www.maylene.uk/about

Media Contact

Organization: Maylene

Contact Person: Sam Aquino

Website: https://www.maylene.uk/

Email: Send Email

Country: United Kingdom

Release id: 49919

View source version on King Newswire:
Maylene Launches UK Research Peptide Platform With Focus on Product Transparency and Scientific Documentation